Neumora Therapeutics, Inc. (NMRA)
(Delayed Data from NSDQ)
$11.79 USD
-0.20 (-1.67%)
Updated Aug 7, 2024 04:00 PM ET
After-Market: $11.82 +0.03 (0.25%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NMRA 11.79 -0.20(-1.67%)
Will NMRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NMRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NMRA
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug
NMRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick
Other News for NMRA
Neumora Therapeutics’ Advancing Drug Pipeline Supports Buy Rating
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Neumora Therapeutics expects cash to fund operations into 2026
Neumora Therapeutics reports Q2 EPS (37c), consensus (37c)